- InvestInvestment SuiteExclusiveFeatures
- PlatformProduct SuiteFeatures and ToolsCalculatorsPricing
- ResearchResearch CallsResearch Reports
- MarketStocksIndicesMutual FundsIPO
- LearnResourceInvesting GuideEvents
- Partner
- Support
Invest
Platform
Research
Market
Learn
Compare ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund vs DSP Healthcare Fund
Fund Comparison
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Fund Details
Risk | Very High | Very High |
Rating | 5.0 | 3.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 1.92 | 1.92 |
NAV | ₹39.04 | ₹41.21 |
Fund Started | 25 Jun 2018 | 12 Nov 2018 |
Fund Size | ₹5044.63 Cr | ₹3248.80 Cr |
Exit Load | Exit load of 1% if redeemed within 15 days. | Exit load of 0.50% if redeemed within 1 month. |
Risk
Very High
Very High
Rating
5.0
3.0
Min SIP Amount
₹100
₹100
Expense Ratio
1.92
1.92
NAV
₹39.04
₹41.21
Fund Started
25 Jun 2018
12 Nov 2018
Fund Size
₹5044.63 Cr
₹3248.80 Cr
Exit Load
Exit load of 1% if redeemed within 15 days.
Exit load of 0.50% if redeemed within 1 month.
Returns
1 Year | 47.49% | 41.56% |
3 Year | 25.74% | 23.06% |
5 Year | 30.32% | 30.86% |
1 Year
47.49%
41.56%
3 Year
25.74%
23.06%
5 Year
30.32%
30.86%
Holding Analysis
Equity | 97.27% | 94.51% |
Cash | 2.73% | 5.49% |
Equity
97.27%
94.51%
Cash
2.73%
5.49%
Top Holdings
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 13.77% |
Dr. Reddy's Laboratories Ltd. | 8.48% |
Cipla Ltd. | 7.94% |
Aurobindo Pharma Ltd. | 5.04% |
Gland Pharma Ltd. | 4.38% |
Lupin Ltd. | 4.29% |
Alkem Laboratories Ltd. | 4.16% |
Zydus Lifesciences Ltd. | 3.10% |
Apollo Hospitals Enterprise Ltd. | 2.93% |
Biocon Ltd. | 2.39% |
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 10.28% |
Suven Pharmaceuticals Ltd. | 10.01% |
Cipla Ltd. | 7.86% |
Ipca Laboratories Ltd. | 7.62% |
Globus Medical Inc | 5.98% |
Illumina Inc. (USA) | 5.23% |
Alembic Pharmaceuticals Ltd. | 4.79% |
Gland Pharma Ltd. | 4.40% |
Apollo Hospitals Enterprise Ltd. | 3.91% |
Concord Biotech Ltd. | 3.82% |
Fund Manager
Name | Dharmesh Kakkad | Jay Kothari |
Start Date | 23 Feb 2021 | 16 Mar 2018 |
Name
Dharmesh Kakkad
Jay Kothari
Start Date
23 Feb 2021
16 Mar 2018
About Fund
Description | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. | The scheme seeks to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies. |
Launch Date | 25 Jun 2018 | 12 Nov 2018 |
Description
The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
The scheme seeks to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies.
Launch Date
25 Jun 2018
12 Nov 2018
